

1 Dose prediction for repurposing nitazoxanide in SARS-CoV-2 2 treatment or chemoprophylaxis

3
4 Rajith KR Rajoli¹, Henry Pertinez¹, Usman Arshad¹, Helen Box¹, Lee Tatham¹, Paul Curley¹, Megan
5 Neary¹, Joanne Sharp¹, Neill J Liptrott¹, Anthony Valentijn¹, Christopher David¹, Steve P Rannard²,
6 Ghaith Aljayoussi³, Shaun H Pennington³, Andrew Hill¹, Marta Boffito^{4,5}, Stephen A Ward³, Saye H
7 Khoo¹, Patrick G Bray⁶, Paul M. O'Neill², W. Dave Hong², Giancarlo Biagini³, Andrew Owen¹.

8
9 ¹Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7
10 3NY, UK

11 ²Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK

12 ³Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool
13 L3 5QA, UK

14 ⁴Chelsea and Westminster NHS Foundation Trust and St Stephen's AIDS Trust 4th Floor, Chelsea and Westminster Hospital,
15 369 Fulham Road, London, SW10 9NH, UK

16 ⁵Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College, London, W2 1PG, UK

17 ⁶Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK

18 19 **Author for correspondence:**

20 Professor Andrew Owen

21 Department of Molecular and Clinical Pharmacology

22 Materials Innovation Factory

23 University of Liverpool

24 51 Oxford Street,

25 Liverpool L7 3NY

26 United Kingdom

27 Email - aowen@liverpool.ac.uk

28 Phone - +44 (0)151 795 7129

29 **Key words:** COVID-19, SARS-CoV-2, Coronavirus, Pharmacokinetics, Lung

30 31 32 **Conflicts of interest statement**

33 AO and SPR are Directors of Tandem Nano Ltd. AO has received research funding from ViiV, Merck,
34 Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. PON is currently
35 engaged in a collaboration with Romark LLC but this interaction did not influence the prioritisation or
36 conclusions in the current manuscript. No other conflicts are declared by the authors.

37 38 **Funding**

39 The authors received no funding for the current work. AO acknowledges research funding from
40 EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission
41 (761104) and Unitaid (project LONGEVITY). GAB acknowledges support from the Medical Research
42 Council (MR/S00467X/1). GA acknowledges funding from the MRC Skills Development Fellowship.

44 Abstract

45

46 **Background:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a
47 global pandemic by the World Health Organisation and urgent treatment and prevention strategies
48 are needed. Many clinical trials have been initiated with existing medications, but assessments of
49 the expected plasma and lung exposures at the selected doses have not featured in the prioritisation
50 process. Although no antiviral data is currently available for the major phenolic circulating
51 metabolite of nitazoxanide (known as tizoxanide), the parent ester drug has been shown to exhibit *in*
52 *vitro* activity against SARS-CoV-2. Nitazoxanide is an anthelmintic drug and its metabolite tizoxanide
53 has been described to have broad antiviral activity against influenza and other coronaviruses. The
54 present study used physiologically-based pharmacokinetic (PBPK) modelling to inform optimal doses
55 of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported
56 nitazoxanide 90% effective concentration (EC₉₀) against SARS-CoV-2.

57 **Methods:** A whole-body PBPK model was constructed for oral administration of nitazoxanide and
58 validated against available tizoxanide pharmacokinetic data for healthy individuals receiving single
59 doses between 500 mg – 4000 mg with and without food. Additional validation against multiple-
60 dose pharmacokinetic data when given with food was conducted. The validated model was then
61 used to predict alternative doses expected to maintain tizoxanide plasma and lung concentrations
62 over the reported nitazoxanide EC₉₀ in >90% of the simulated population. Optimal design software
63 PopDes was used to estimate an optimal sparse sampling strategy for future clinical trials.

64 **Results:** The PBPK model was validated with AAFE values between 1.01 – 1.58 and a difference less
65 than 2-fold between observed and simulated values for all the reported clinical doses. The model
66 predicted optimal doses of 1200 mg QID, 1600 mg TID, 2900 mg BID in the fasted state and 700 mg
67 QID, 900 mg TID and 1400 mg BID when given with food, to provide tizoxanide plasma and lung
68 concentrations over the reported *in vitro* EC₉₀ of nitazoxanide against SARS-CoV-2. For BID regimens
69 an optimal sparse sampling strategy of 0.25, 1, 3 and 12h post dose was estimated.

70 **Conclusion:** The PBPK model predicted that it was possible to achieve plasma and lung tizoxanide
71 concentrations, using proven safe doses of nitazoxanide, that exceed the EC₉₀ for SARS-CoV-2. The
72 PBPK model describing tizoxanide plasma pharmacokinetics after oral administration of nitazoxanide
73 was successfully validated against clinical data. This dose prediction assumes that the tizoxanide
74 metabolite has activity against SARS-CoV-2 similar to that reported for nitazoxanide, as has been
75 reported for other viruses. The model and the reported dosing strategies provide a rational basis for
76 the design (optimising plasma and lung exposures) of future clinical trials of nitazoxanide in the
77 treatment or prevention of SARS-CoV-2 infection.

78 Introduction

79

80 COVID-19 is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-
81 CoV-2) with noticeable symptoms such as fever, dry cough, and difficulty in breathing. There are
82 currently no effective treatment or prevention options and it has become a global health problem
83 with more than 3.1 million cases and over 217,000 deaths as of 29th April 2020 [1]. Urgent strategies
84 are required to manage the pandemic and the repurposing of already approved medicines is likely to
85 bring options forward more quickly than full development of potent and specific antivirals. Antiviral
86 drugs may have application prior to or during early infection, but may be secondary to
87 immunological interventions in later stages of severe disease [2].

88

89 Although new chemical entities (NCEs) are likely to have high potency and specificity for SARS-CoV-2,
90 full development is time consuming, costly and attrition in drug development is high [3, 4]. Drug
91 repurposing, where existing or investigational drugs could be used outside the scope of their original
92 indication may present a rapid alternative to new drug development. Several examples of successful
93 repurposing exist, including the use of the anti-angiogenic drug thalidomide for cancer and the use
94 of mifepristone for Cushing's disease after initially being approved for termination of early
95 pregnancy [5, 6].

96

97 SARS-CoV-2 targets the angiotensin-converting enzyme 2 (ACE2) receptors that are present in high
98 density on the outer surface of lung cells. Lungs are the primary site of SARS-CoV-2 replication and
99 infection is usually initiated in the upper respiratory tract [7]. Symptoms that result in neurological,
100 renal and hepatic dysfunction are also emerging due to the expression of ACE2 receptors in these
101 organs [8-11]. Therefore, therapeutic concentrations of antiviral drugs are likely to be needed in the
102 upper airways for treatment and prevention of infection, but sufficient concentrations are also likely
103 to be required systemically for therapy to target the virus in other organs and tissues.

104

105 The scale at which antiviral activity of existing medicines are being studied for potential repurposing
106 against SARS-CoV-2 is unprecedented [12]. The authors recently reported a holistic analysis which
107 benchmarked reported *in vitro* activity of tested drugs against previously published pharmacokinetic
108 exposures achievable with their licenced doses [13]. Importantly, this analysis demonstrated that the
109 majority of drugs that have been studied for anti-SARS-CoV-2 activity are unlikely to achieve the
110 necessary concentrations in the plasma after administration of their approved doses. While this
111 analysis is highly influenced by the drugs selected for analysis to date and highly sensitive to the

112 accuracy of the reported antiviral activity data, a number of candidate agents were identified with
113 plasma exposures above the reported EC_{50}/EC_{90} against SARS-CoV-2.

114

115 One such drug, nitazoxanide, is a thiazolide antiparasitic medicine used for the treatment of
116 cryptosporidiosis and giardiasis that cause diarrhoea [14, 15], and also has reported activity against
117 anaerobic bacteria, protozoa and other viruses [16]. Importantly, rapid deacetylation of nitazoxanide
118 in blood means that the major systemic species of the drug *in vivo* is tizoxanide, which has not yet
119 been studied for anti-SARS-CoV-2 activity. Notwithstanding, tizoxanide has been shown to exhibit
120 similar *in vitro* inhibitory activity to nitazoxanide for rotaviruses [17], hepatitis B and C viruses [18,
121 19], other coronaviruses, noroviruses [20] and influenza viruses [21, 22]. As another respiratory
122 virus, previous work on influenza may be useful to gain insight into the expected impact of
123 nitazoxanide for SARS-CoV-2. Accordingly, the drug has been shown to selectively block the
124 maturation of the influenza hemagglutinin glycoprotein at the post-translational stage [22, 23] and a
125 previous phase 2b/3 trial demonstrated a reduction in symptoms and viral shedding at a dose of 600
126 mg BID compared to placebo in patients with uncomplicated influenza [24]. Other potential benefits
127 of nitazoxanide in COVID-19 may derive from its impact upon the innate immune response that
128 potentiates the production of type 1 interferons [25, 26] and bronchodilation of the airways through
129 inhibition of TMEM16A ion channels [27]. A clinical trial (NCT04341493) started on April 6th 2020 and
130 aims to evaluate the activity of 500 mg BID nitazoxanide alone or in combination with the 4-
131 aminoquinoline hydroxychloroquine against SARS-CoV-2 [28]. However, there are currently no data
132 within the public domain to support this dose selection for COVID-19. Nitazoxanide is relatively safe
133 in humans and studies showed tolerability of single oral doses up to 4 g with minimal
134 gastrointestinal side effects. Plasma concentrations of tizoxanide have demonstrated dose
135 proportionality, but administration in the fed state increases the plasma exposure [29]. Thus, the
136 drug is recommended for administration with food.

137

138 Physiologically-based pharmacokinetic (PBPK) modelling is a computational tool that integrates
139 human physiology and drug disposition kinetics using mathematical equations to inform the
140 pharmacokinetic exposure using *in vitro* and drug physicochemical data [30]. The aim of this study
141 was to validate a PBPK model for tizoxanide following administration of nitazoxanide. Once validated
142 this model was first used to assess the plasma and lung exposures estimated to be achieved during a
143 previous trial for uncomplicated influenza. Next, different nitazoxanide doses and schedules were
144 simulated to identify those expected to provide tizoxanide plasma and lung trough concentrations
145 (C_{trough}) above the reported nitazoxanide SARS-CoV-2 EC_{90} in the majority (>90%) of patients.

146 **Methods**

147

148 A whole-body PBPK model consisting of compartments to represent select organs and tissues was
149 developed. Nitazoxanide physiochemical and drug-specific parameters used in the PBPK model were
150 obtained from literature sources as outlined in Table 1. The PBPK model was assumed to be blood-
151 flow limited, with instant and uniform distribution in each tissue or organ and no reabsorption from
152 the large intestine. Since the data is computer generated, no ethics approval was required for this
153 study.

154

155 **Table 1** Nitazoxanide input parameters for the PBPK model

Parameter	Nitazoxanide	Tizoxanide
Molecular weight	307.282 [15]	265.25 [31]
*Protein binding	>99% [15]	>99% [32]
Log P	1.63 [15]	3.2 [31]
pKa (acidic)	8.3 [15]	6.7 [33]
R	0.55	0.55
Number of hydrogen bond donors	1 [15]	2 [31]
Polar surface area	114.11 [15]	136 [31]
Apparent permeability (cm/s)	1.11e-4 [34]	-
Apparent clearance (L/h)	-	19.34 ± 4.97 [35]
Volume of distribution (L)	-	38.68 ± 14.02 [35]
Half-life (h)	-	1.38 ± 0.29 [35]

156 R – blood to plasma ratio was predicted from Paixão et al. [36], – not available, apparent permeability was
157 assessed in HT29-19A cells and this value was considered the same in caco-2 cells for tizoxanide, *protein
158 binding was considered as 99% for the PBPK model

159

160 **Model development**

161 One hundred virtual healthy adults (50% women, aged 20-60 years between 40-120 kg) were
162 simulated. Patient demographics such as weight, BMI and height were obtained from CDC charts
163 [37]. Organ weight/volumes and blood flow rates in humans were obtained from published
164 literature sources [38, 39]. Transit from the stomach and small intestine was divided into seven
165 compartments to capture effective absorption kinetics as previously described [40]. Tissue to plasma
166 partition ratio of drug and drug disposition across various tissues and organs were described using
167 published mathematical equations [41-43]. Effective permeability (P_{eff}) in humans was scaled from
168 apparent permeability (P_{app}) in HT29-19A cells (due to lack of available data, it was assumed the

169 same in Caco-2 cells) using the following equations to compute the rate of absorption (K_a in h^{-1}) from
170 the small intestine.

171

$$172 \log_{10} P_{eff} = 0.6836 \times \log_{10} P_{app} - 0.5579 \quad [44]$$

173

$$174 K_a = \frac{2 \times P_{eff} \times 60 \times 60}{r} \quad [45]$$

175

176 **Model validation**

177 The PBPK model was validated against available clinical data in healthy individuals in the fed and
178 fasted state for various single oral doses of nitazoxanide ranging from 500 mg to 4000 mg [29, 46],
179 and for multiple dosing at 500 mg and 1000 mg BID with food. Nitazoxanide absorption was
180 considered using the available apparent permeability data (shown in table 1) and tizoxanide was
181 assumed to form as soon as the drug reached systemic circulation as metabolic studies have shown
182 it takes just six minutes for complete conversion into the active circulating metabolite, with no trace
183 of nitazoxanide detected in plasma [47]. Therefore, tizoxanide parameters were used to define drug
184 disposition. The model was assumed to be validated if: 1) the absolute average fold error (AAFE)
185 between the observed and the simulated plasma concentrations - time curve of tizoxanide was less
186 than two; and 2) the simulated pharmacokinetic parameters - maximum concentration (C_{max}), area
187 under the plasma concentration-time curve (AUC) and C_{trough} (trough concentration at the end of the
188 dosing interval) were less than two-fold from the mean observed values.

189

190 **Model simulations**

191 The pharmacokinetics following administration of 600 mg BID as reported in a previous phase 2b/3
192 clinical trial of nitazoxanide in uncomplicated influenza [24] were first simulated and plotted relative
193 to the average of previously reported influenza EC_{90s} [48, 49] for strains (as shown in supplementary
194 table 1) included in the previous trials. This was done to assess the exposure relative to *in vitro*
195 activity for an indication where clinical benefit was already demonstrated.

196

197 For potential SARS-CoV-2 applications, several oral dosing regimens were simulated for BID, TID or
198 QID administration in the fasted state. Antiviral activity data from Wang et al. [50] were digitised
199 using Web Plot Digitiser® software and used to calculate a nitazoxanide EC_{90} for SARS-CoV-2 of 4.64
200 μM (1.43 mg/L). Optimal doses were identified such that the concentration at 12 hours post-first
201 dose (C_{12}) for BID, 8 hours post-first dose (C_8) for TID, or 6 hours post-first dose (C_6) for QID
202 administration were over the recalculated EC_{90} for nitazoxanide. Plasma and lung tizoxanide

203 exposures at these doses and schedules are reported in addition to plasma-time curves. The doses
204 were optimised using tizoxanide parameters and pharmacokinetics, however, the doses were
205 reported for nitazoxanide.

206

207 **Optimal pharmacokinetic sampling**

208 Clinical trials should incorporate PK sampling to confirm tizoxanide plasma exposures, and further
209 validate the predictions from the PBPK model. Optimal sparse pharmacokinetic timepoint selection
210 (assuming 4 blood samples per patient, and 40 patients in the study) were made on the basis of the
211 prior fed PK data of Stockis et al. [29, 46]. Tizoxanide plasma PK data in fed patients from Stockis et
212 al. was fitted with an empirical one compartment disposition model, with first-order absorption and
213 absorption transit compartment, and the parameters from this fitting were used (with nominal %CV
214 interindividual variability in the PK parameters of 30%) in the optimal design software PopDes
215 (University of Manchester Version 4.0) to generate the suggested optimal sampling timepoints [51,
216 52].

217

218 **Results**


219 **Model validation**

220 The PBPK model validation against various fasted oral doses is shown in supplementary Figure 1 and
221 the validation against single and multiple doses in the fed state is shown in supplementary Figure 2.
222 The corresponding pharmacokinetic parameters (AUC, C_{max} and C_{trough}) are presented in Table 2a and
223 2b. The AAFE values for the validated doses ranged between 1.01 – 1.55 for fasted state and
224 between 1.1 – 1.58 for fed state indicating a close match between observed and simulated data. The
225 ratio between the simulated and the observed pharmacokinetic parameters – AUC, C_{max} and C_{trough}
226 was between 0.81 – 1.54 (Table 2a) for fasted state and between 0.67 – 2.15 for fed state. The PBPK
227 model simulated tizoxanide plasma concentrations were within acceptable ranges and therefore the
228 PBPK model was assumed to be validated.


229 **Model simulations**

230 Figure 1a and 1b show the simulated plasma and lung exposures relative to the average influenza
231 EC_{90} after administration of 600 mg BID dose of nitazoxanide with food as reported in the previous
232 phase 2b/3 trial in uncomplicated influenza [24]. These simulations indicate that all patients were
233 predicted to have plasma and lung tizoxanide C_{trough} (C_{12}) concentrations below the average EC_{90} (8.4
234 mg/L, supplementary table 1) [49], but that 71% and 14% were predicted to have plasma and lung
235 C_{max} concentrations respectively above the average EC_{90} for influenza, respectively.

236
237 Figure 2a and 2b shows the prediction of trough concentrations in plasma and lung for the different
238 simulated doses and schedules in healthy individuals for fasted and fed states, respectively. Doses
239 and schedules estimated to provide plasma C_{trough} concentrations over 1.43 mg/L for at least 50% of
240 the simulated population were identified. However, lower doses in each schedule (i.e. 800 mg QID,
241 1300 mg TID and 1800 mg BID in fasted state and 500 mg QID, 700 mg TID, 1100 mg BID in fed state)
242 were predicted to result in >40% of the simulated population having lung C_{trough} below the SARS-CoV-
243 2 EC_{90} . Optimal doses for SARS-CoV-2 in the fasted state were predicted to be 1200 mg QID, 1600 mg
244 TID, 2900 mg BID and in the fed state were 700 mg QID, 900 mg TID and 1400 mg BID. Figure 3
245 shows the plasma and lung concentrations for the optimal doses and schedules in fed state and
246 supplementary figure 3 shows the plasma concentration – time profile of optimal doses in fasted
247 state. Tizoxanide concentrations in lung and plasma were predicted to reach steady state in <48
248 hours, both in the fasted and fed state.



249



250

251 **Figure 1** Stimulated plasma (a) and lung (b) concentration for nitazoxanide 600 mg BID for 5 days
252 with food relative to the average reported tizoxanide EC_{90} value for influenza strains (supplementary
253 table 1) similar to those in a previous phase IIb/III trial in uncomplicated influenza [24].

254

255 **Table 2a** Tizoxanide validation against observed data for various single oral doses in the fasted state

Dose (mg)	Pharmacokinetic parameter	Observed	Simulated	Simulated/observed
500 [46]	*AUC _{0-12 h} (µg.h/ml)	27.02 ± 6.24	24.32 ± 5.07	0.90
	*C _{max} (µg/ml)	6.80 ± 1.32	6.47 ± 1.17	0.95
	[†] C _{trough} (µg/ml)	0.106	0.119 ± 0.185	1.12
1000 [29]	[^] AUC _{0-24 h} (µg.h/ml)	50.6 (29.0 – 88.4)	48.9 (34.3 – 63.4)	0.93
	[^] C _{max} (µg/ml)	12.3 (8.21 – 18.3)	12.9 (10.2 – 12.9)	1.05
	[†] C _{trough} (µg/ml)	0.23	0.21 (0.09 – 0.53)	0.93
2000 [29]	[^] AUC _{0-24 h} (µg.h/ml)	59.2 (36.5 – 95.9)	68.5 (48.9 – 84.1)	1.12
	[^] C _{max} (µg/ml)	9.08 (7.07 – 11.7)	9.45 (7.18 – 11.7)	1.04
	^{^†} C _{trough} (µg/ml)	1.49	1.33 (0.45 – 2.21)	0.89
3000 [29]	[^] AUC _{0-24 h} (µg.h/ml)	52.9 (34.6 – 81.0)	42.6 (31.7 – 53.6)	0.81
	[^] C _{max} (µg/ml)	7.39 (6.07 – 8.98)	7.51 (5.68 – 9.33)	1.02
	^{^†} C _{trough} (µg/ml)	0.6	0.93 (0.79 – 1.06)	1.54
4000 [29]	[^] AUC _{0-24 h} (µg.h/ml)	88.5 (53.5 – 146)	76.9 (60.1 – 93.8)	0.87
	[^] C _{max} (µg/ml)	10.5 (8.16 – 13.5)	9.58 (7.34 – 11.8)	0.91
	^{^†} C _{trough} (µg/ml)	2.48	2.44 (2.19 – 2.67)	0.98


256 *C_{max} and AUC_{0-12h} are represented as arithmetic mean ± SD, [^]C_{max} and AUC_{0-24h} are represented as geometric mean (mean – SD, mean + SD), [†]C_{trough} is C₁₂ and
 257 has been digitised from the pharmacokinetic curve as the geometric mean is not available, arithmetic mean is shown for observed and arithmetic mean
 258 (mean - SD, mean + SD) are shown for simulated data, [^]C_{max}, AUC_{0-24h} and [^]C_{trough} were normalised to a 1000 mg dose.

259 **Table 2b** Tizoxanide validation against observed data for various single and multiple oral doses when given with food.

Dose (mg)	Pharmacokinetic parameter	Observed	Simulated	Simulated/observed
500 (single) [53]	*AUC _{0-last} (µg.h/ml)	41.8 (36.1 – 48.4)	33.2 (23.1 - 43.2)	0.79
	C _{max} (µg/ml)	10.4 (8.65 – 12.6)	8.08 (6.17 - 9.98)	0.78
	†C _{trough} (µg/ml)	0.178	0.28 (0 - 0.5)	1.56
500 BID (multiple) [53]	*AUC _{0-12 h} (µg.h/ml)	48.7 (36.0 – 65.9)	32.8 (19.5 - 46.1)	0.67
	C _{max} (µg/ml)	9.05 (7.13 – 11.5)	7.66 (5.89 - 9.44)	0.85
	†C _{trough} (µg/ml)	0.310	0.35 (0 - 0.89)	1.11
1000 (single) [53]	*AUC _{0-last} (µg.h/ml)	85.9 (68.8 – 107)	91.3 (69 - 113.5)	1.06
	C _{max} (µg/ml)	14.4 (10.8 – 19.2)	17.8 (14.3 - 21.3)	1.23
	†C _{trough} (µg/ml)	0.786	1.43 (0.2 - 2.22)	1.82
1000 BID (multiple) [53]	*AUC _{0-12 h} (µg.h/ml)	144 (105 – 198)	90.9 (69 - 112.8)	0.63
	C _{max} (µg/ml)	24.2 (20.3 – 28.7)	18.2 (14.4 - 21.9)	0.75
	†C _{trough} (µg/ml)	1.68	1.38 (0.33 - 2.07)	0.82
2000 (single) [29]	^AUC _{0-24 h} (µg.h/ml)	110 (88.0 – 139)	109 (74.8 - 142)	0.99
	^C _{max} (µg/ml)	15.8 (13.0 – 19.2)	14.3 (11.2 - 17.4)	0.91
	^†C _{trough} (µg/ml)	1.52	3.27 (1.73 - 4.46)	2.15
3000 (single) [29]	^AUC _{0-24 h} (µg.h/ml)	95.3 (60.0 – 152)	90 (60.9 - 119)	0.94
	^C _{max} (µg/ml)	10.0 (7.40 – 13.5)	10.4 (8.09 - 12.7)	1.04
	^†C _{trough} (µg/ml)	2.35	2.64 (1.44 - 3.56)	1.12

4000 (single) [29]	$\hat{AUC}_{0-24\text{ h}}$ ($\mu\text{g}\cdot\text{h}/\text{ml}$)	192 (99.5 – 370)	161 (125 - 196)	0.84
	\hat{C}_{max} ($\mu\text{g}/\text{ml}$)	17.5 (11.5 – 26.5)	14.2 (11.2 - 17.2)	0.81
	\hat{C}_{trough} ($\mu\text{g}/\text{ml}$)	6.55	6.52 (5.04 - 7.84)	0.99

260 C_{max} and AUC are represented as geometric mean (mean – SD, mean + SD) and \hat{C}_{max} and $AUC_{0-24\text{h}}$ were normalised to a 1000 mg dose, \hat{C}_{max} and $AUC_{0-24\text{h}}$
261 were normalised to a 1000 mg dose, \hat{AUC} is represented as $AUC_{0-\infty}$ after the first dose for single and AUC_{0-12} on day 7, \hat{C}_{trough} is C_{12} has been digitised from
262 the pharmacokinetic curve as the geometric mean is not available, arithmetic mean is shown for observed and arithmetic mean (mean - SD, mean + SD) are
263 shown for simulated data.




264

265 **Figure 2a** Predicted tizoxanide C_{trough} (BID – 12 h, TID – 8 h, QID – 6 h) for various dosing regimens of nitazoxanide in fasted state at the end of the first dose.

266 Data is presented as mean and error bars represent standard deviation. The percentages adjacent to the bar chart indicate the percentage of simulated

267 population over EC_{90} of nitazoxanide for SARS-CoV-2.




268

269 **Figure 2b** Predicted tizoxanide C_{trough} (BID – 12 h, TID – 8 h, QID – 6 h) for various dosing regimens of nitazoxanide in fed state at the end of the first dose.

270 Data is presented as mean and error bars represent standard deviation. The percentages adjacent to the bar chart indicate the percentage of simulated


271 population over EC₉₀ of nitazoxanide for SARS-CoV-2.

272




273

274



275

276



277

278 **Figure 3** Predicted plasma and lung concentrations for optimal doses during the fed state at different

279 regimens reaching steady state – A) 1400 mg BID, B) 900 mg TID and C) 700 mg QID. TIZ – tizoxanide,

280 SD – standard deviation, solid red line indicates clinical C_{max} of 1 g single dose at fed state [29], solid

281 green line represents clinical C_{max} of 500 mg single dose [53] at fed state and the dotted red line

282 represents the EC_{90} of nitazoxanide for SARS-CoV-2 [50].

283

284 **Optimal sparse sampling design**

285 Results from PopDes optimal design procedure indicate pharmacokinetic sampling timepoints at

286 0.25, 1, 3 and 12h post dose for BID regimens, and 0.25, 1, 2 and 8h post dose for TID regimens.

287 Discussion

288 Treatment of SARS-CoV-2 has become a major global healthcare challenge with no well-defined
289 therapeutic agents to either treat or prevent the spread of the infection. Short-term treatment
290 options are urgently required but many ongoing trials are not based upon a rational selection of
291 candidates in the context of safe achievable drug exposures. In the absence of a vaccine, there is
292 also an urgent need for chemo preventative strategies to protect those at high risk such as
293 healthcare staff, key workers and household contacts who are more vulnerable to infection.
294 Nitazoxanide has emerged as a potential candidate for repurposing for COVID-19. The PBPK model
295 presented herein was validated with an acceptable variation in AAFE and simulated/observed ratio
296 (close to 1), which provides confidence in the presented predictions. The present study aimed to
297 define the optimal doses and schedules for maintaining tizoxanide plasma and lung concentrations
298 above the reported nitazoxanide EC₉₀ for the duration of the dosing interval.

299
300 Nitazoxanide was assessed in a double-blind, randomised, placebo-controlled, phase 2b/3 trial
301 (NCT01227421) of uncomplicated influenza in 74 primary care clinics in the USA between 27 Dec
302 2010 and 30 April 2011 [54]. The median duration of symptoms for patients receiving placebo was
303 117 h compared with 96 h in patients receiving 600 mg BID nitazoxanide with food. Importantly,
304 virus titre in nasopharyngeal swabs in 39 patients receiving nitazoxanide 600 mg BID were also lower
305 than in 41 patients receiving placebo. The average of reported tizoxanide EC_{90S} for influenza A and B
306 [55] was calculated to be 8.4 mg/L, which is higher than the one reported EC₉₀ for nitazoxanide
307 against SARS-CoV-2 [50]. The PBPK model was used to simulate plasma and lung exposures after
308 administration of 600 mg BID for 5 days, and while only plasma C_{max} exceeded the average influenza
309 EC₉₀ in the majority of patients, the C_{trough} values did not. The modelling data suggest that the
310 moderate effects of nitazoxanide seen in influenza could be a function of under dosing. Taken
311 collectively, these data are encouraging for the application of nitazoxanide in COVID-19, assuming
312 that tizoxanide displays anti-SARS-CoV-2 activity comparable to that reported for nitazoxanide.
313 Moreover, these simulations indicate that higher doses may be optimal for maximal suppression of
314 pulmonary viruses.

315
316 In some cases, food intake may be difficult in patients with COVID-19 so drugs that can be given
317 without regard for food may be preferred. However, the presented predictions indicate that optimal
318 plasma and lung exposures would require 1200 mg QID, 1600 mg TID or 2900 mg BID in the fasted
319 state. Conversely, the PBPK models predict that doses of 700 mg QID, 900 mg TID or 1400 mg BID
320 with food provide tizoxanide concentrations in plasma and lung above the EC₉₀ value for

321 nitazoxanide for the entire dosing interval in at least 90% of the simulated population. Single doses
322 up to 4000 mg have been administered to humans previously [29] but the drug is usually
323 administered at 500 mg BID.. The PBPK model simulations indicate a high BID dose of 1400 mg (fed)
324 and caution may be needed for gastrointestinal intolerance at this dose. The simulations indicate
325 that lower TID and QID dosing regimens may also warrant investigation, and 900 mg TID as well as
326 700 mg QID (both with food) regimen are also predicted to provide optimal exposures for efficacy.
327 Importantly, the overall daily dose was estimated to be comparable between the different optimal
328 schedules and it is unclear whether splitting the dose will provide gastrointestinal benefits. For
329 prevention application where individuals will need to adhere to regimens for longer durations,
330 minimising the frequency of dosing is likely to provide adherence benefits. However, for short term
331 application in therapy, more frequent dosing may be more acceptable to minimise gastrointestinal
332 intolerance.

333
334 Nitazoxanide mechanism of action for SARS-CoV-2 is currently unknown. However, for influenza it
335 has been reported to involve interference with N-glycosylation of hemagglutinin [22, 55, 56]. Since
336 the SARS-CoV-2 spike protein is also heavily glycosylated [57] with similar cellular targets in the
337 upper respiratory tract, a similar mechanism of action may be expected [7, 58]. An ongoing trial in
338 Mexico, is being conducted with 500 mg BID nitazoxanide with food [28] but these doses may not be
339 completely optimal for virus suppression across the entire dosing interval.

340
341 This analysis provides a rational dose optimisation for nitazoxanide for treatment and prevention of
342 COVID-19. However, there are some important limitations that must be considered. PBPK models
343 can be useful in dose prediction but the quality of predictions is only as good as the quality of the
344 available data on which they are based. Furthermore, the mechanism of action for nitazoxanide for
345 other viruses has also been postulated to involve an indirect mechanism through amplification of the
346 host innate immune response [59], and this would not have been captured in the in vitro antiviral
347 activity that informed the target concentrations for this dose prediction. The simulated population
348 used in this modelling consisted of healthy individuals up to 60 years old, but many patients
349 requiring therapy may be older and have underlying comorbidities. To best knowledge, the impact of
350 renal and hepatic impairment on pharmacokinetics of this drug have not been assessed and may
351 impact the pharmacokinetics. Although the current PBPK model is validated against various single
352 doses in the fasted state and few multiple doses when given with food, the model may predict with
353 less accuracy for multiple doses due to the unavailability of clinical data for multiple dosing over
354 1000 mg. The presented models were validated using BID doses only, and confidence in the

355 predictions for TID and QID doses may be lower. The clinical studies used for model validation were
356 performed in a limited number of patients [29] and thus may underrepresent real inter-subject
357 variability. Also, the disposition parameters (apparent clearance and rate of absorption) obtained for
358 the PBPK model were from a fasted study of 500 mg BID, and the parameters were adjusted to
359 validate the tizoxanide model in the fed state, which may limit confidence in the model at higher
360 doses. Only one manuscript has described the *in vitro* activity of nitazoxanide against SARS-CoV-2
361 [50] and no data are available for tizoxanide. Reported in vitro data may vary across laboratories and
362 due to this the predicted optimal doses may change. However, the reported comparable activity of
363 nitazoxanide and tizoxanide against a variety of other viruses (including other coronaviruses) does
364 strengthen the rationale for investigating this drug for COVID-19 [17-19, 21, 22]. Finally, none of the
365 reported EC₉₀ values for influenza or SARS-CoV-2 were protein binding-adjusted [50] and tizoxanide
366 is known to be highly protein bound (>99%) in plasma [32]. Therefore, while the protein binding was
367 used to estimate drug penetration into the lung, data were not available to correct the *in vitro*
368 activity.

369

370 In summary, the developed PBPK model of nitazoxanide was successfully validated against clinical
371 data and based on currently available data, optimal doses for COVID-19 were estimated to be 700
372 mg QID, 900 mg TID or 1400 mg BID with food. Should nitazoxanide be progressed into clinical
373 evaluation for treatment and prevention of COVID-19, it will be important to further evaluate the
374 pharmacokinetics in these population groups. In treatment trials particularly, intensive
375 pharmacokinetic sampling may be challenging. Therefore, an optimal sparse sampling strategy for
376 BID, TID and QID dosing is also presented.

377

378 References

- 379 1. Johns Hopkins University of Medicine. *Coronavirus Resource Center*. 2020 [cited 2020
380 17/04/2020]; Available from: <https://coronavirus.jhu.edu/map.html>.
- 381 2. Zhang, W., et al., *The use of anti-inflammatory drugs in the treatment of people with severe
382 coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China*.
383 Clinical immunology (Orlando, Fla.), 2020. **214**: p. 108393-108393.
- 384 3. Gns, H.S., et al., *An update on Drug Repurposing: Re-written saga of the drug's fate*.
385 Biomedicine & Pharmacotherapy, 2019. **110**: p. 700-716.
- 386 4. Charlton, R.L., et al., *Repurposing as a strategy for the discovery of new anti-leishmanials:
387 the-state-of-the-art*. Parasitology, 2018. **145**(2): p. 219-236.
- 388 5. Telleria, C.M., *Drug Repurposing for Cancer Therapy*. Journal of cancer science & therapy,
389 2012. **4**(7): p. ix-xi.
- 390 6. Senanayake, S.L., *Drug repurposing strategies for COVID-19*. Future Drug Discovery, 2020.
391 **2**(2): p. null.
- 392 7. Shereen, M.A., et al., *COVID-19 infection: Origin, transmission, and characteristics of human
393 coronaviruses*. Journal of Advanced Research, 2020. **24**: p. 91-98.
- 394 8. Adhikari, S.P., et al., *Epidemiology, causes, clinical manifestation and diagnosis, prevention
395 and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping
396 review*. Infectious Diseases of Poverty, 2020. **9**(1): p. 29.
- 397 9. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. New
398 England Journal of Medicine, 2020. **382**(8): p. 727-733.
- 399 10. Xu, H., et al., *High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral
400 mucosa*. International Journal of Oral Science, 2020. **12**(1): p. 8.
- 401 11. Toljan, K., *Letter to the Editor Regarding the Viewpoint "Evidence of the COVID-19 Virus
402 Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic
403 Mechanism"*. ACS Chemical Neuroscience, 2020. **11**(8): p. 1192-1194.
- 404 12. Sanders, J.M., et al., *Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A
405 Review*. JAMA, 2020.
- 406 13. Arshad, U., et al., *Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities
407 based on ability to achieve adequate target site concentrations derived from their
408 established human pharmacokinetics*. medRxiv, 2020: p. 2020.04.16.20068379.
- 409 14. Wilson, C.M., *296 - Antiparasitic Agents*, in *Principles and Practice of Pediatric Infectious
410 Diseases (Fourth Edition)*, S.S. Long, Editor. 2012, Content Repository Only!: London. p. 1518-
411 1545.e3.
- 412 15. DrugBank. *Nitazoxanide*. 2020 [cited 2020 17/04/2020]; Available from:
413 <https://www.drugbank.ca/drugs/DB00507>.
- 414 16. Keiser, J. and J. Utzinger, *Chapter 8 - The Drugs We Have and the Drugs We Need Against
415 Major Helminth Infections*, in *Advances in Parasitology*, X.-N. Zhou, et al., Editors. 2010,
416 Academic Press. p. 197-230.
- 417 17. Rossignol, J.F. and Y.M. El-Gohary, *Nitazoxanide in the treatment of viral gastroenteritis: a
418 randomized double-blind placebo-controlled clinical trial*. Alimentary Pharmacology &
419 Therapeutics, 2006. **24**(10): p. 1423-1430.
- 420 18. Korba, B.E., et al., *Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide*.
421 Antimicrobial Agents and Chemotherapy, 2008. **52**(11): p. 4069-4071.
- 422 19. Korba, B.E., et al., *Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of
423 hepatitis B virus and hepatitis C virus replication*. Antiviral Research, 2008. **77**(1): p. 56-63.
- 424 20. Dang, W., et al., *Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with
425 Ribavirin by Activation of Cellular Antiviral Response*. Antimicrobial Agents and
426 Chemotherapy, 2018. **62**(11): p. e00707-18.
- 427 21. Koszalka, P., D. Tilmanis, and A.C. Hurt, *Influenza antivirals currently in late-phase clinical
428 trial*. Influenza and other respiratory viruses, 2017. **11**(3): p. 240-246.

- 429 22. Rossignol, J.-F., *Nitazoxanide: A first-in-class broad-spectrum antiviral agent*. Antiviral
430 Research, 2014. **110**: p. 94-103.
- 431 23. Pizzorno, A., et al., *Drug Repurposing Approaches for the Treatment of Influenza Viral*
432 *Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy*. Frontiers in Immunology,
433 2019. **10**(531).
- 434 24. Haffizulla, J., et al., *Effect of nitazoxanide in adults and adolescents with acute*
435 *uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial*.
436 Lancet Infect Dis, 2014. **14**(7): p. 609-18.
- 437 25. Rossignol, J.F., *Nitazoxanide: a first-in-class broad-spectrum antiviral agent*. Antiviral Res,
438 2014. **110**: p. 94-103.
- 439 26. Clerici, M., et al., *The anti-infective Nitazoxanide shows strong immunomodulating effects*
440 *(155.21)*. 2011. **186**(1 Supplement): p. 155.21-155.21.
- 441 27. Miner, K., et al., *Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are*
442 *Potent TMEM16A Antagonists That Fully Bronchodilate Airways*. Frontiers in pharmacology,
443 2019. **10**: p. 51-51.
- 444 28. ClinicalTrials.gov. *Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19*. 2020
445 [cited 2020 17/04/2020]; Available from: <https://clinicaltrials.gov/ct2/show/NCT04341493>.
- 446 29. Stockis, A., et al., *Nitazoxanide pharmacokinetics and tolerability in man using single*
447 *ascending oral doses*. International Journal of Clinical Pharmacology and Therapeutics, 2002.
448 **40**(5): p. 213-220.
- 449 30. Yao, X., et al., *In Vitro Antiviral Activity and Projection of Optimized Dosing Design of*
450 *Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2*
451 *(SARS-CoV-2)*. Clinical Infectious Diseases, 2020.
- 452 31. Pubchem. *Tizoxanide*. 2020 [cited 2020 24/04/2020]; Available from:
453 <https://pubchem.ncbi.nlm.nih.gov/compound/Tizoxanide>.
- 454 32. Drugs.com. *Nitazoxanide*. 2020 [cited 2020 18/04/2020]; Available from:
455 <https://www.drugs.com/ppa/nitazoxanide.html>.
- 456 33. Shalan, S., J.J. Nasr, and F. Belal, *Determination of tizoxanide, the active metabolite of*
457 *nitazoxanide, by micellar liquid chromatography using a monolithic column. Application to*
458 *pharmacokinetic studies*. Analytical Methods, 2014. **6**(21): p. 8682-8689.
- 459 34. Matysiak-Budnik, T., F. Mégraud, and M. Heyman, *In-vitro transfer of nitazoxanide across the*
460 *intestinal epithelial barrier*. Journal of Pharmacy and Pharmacology, 2002. **54**(10): p. 1413-
461 1417.
- 462 35. Marcelín-Jiménez, G., et al., *Development of a method by UPLC–MS/MS for the*
463 *quantification of tizoxanide in human plasma and its pharmacokinetic application*.
464 Bioanalysis, 2012. **4**(8): p. 909-917.
- 465 36. Paixão, P., L.F. Gouveia, and J.A.G. Morais, *Prediction of drug distribution within blood*.
466 European Journal of Pharmaceutical Sciences, 2009. **36**(4–5): p. 544-554.
- 467 37. Prevention, C.f.D.C.a. *Anthropometric Reference Data for Children and Adults: United States,*
468 *2011–2014*. 2016 [cited 2019 17/10/2019]; Available from:
469 https://www.cdc.gov/nchs/data/series/sr_03/sr03_039.pdf.
- 470 38. Williams, L.R., *Reference values for total blood volume and cardiac output in humans*. 1994.
- 471 39. Bosgra, S., et al., *An improved model to predict physiologically based model parameters and*
472 *their inter-individual variability from anthropometry*. Crit Rev Toxicol, 2012. **42**(9): p. 751-
473 767.
- 474 40. Yu, L.X. and G.L. Amidon, *A compartmental absorption and transit model for estimating oral*
475 *drug absorption*. Int J Pharm, 1999. **186**(2): p. 119-125.
- 476 41. Peters, S., *Evaluation of a Generic Physiologically Based Pharmacokinetic Model for*
477 *Lineshape Analysis*. Clin Pharmacokinet 2008. **47**(4): p. 261-275.

- 478 42. Rodgers, T., D. Leahy, and M. Rowland, *Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases*. Journal of Pharmaceutical Sciences, 2005. **94**(6): p. 1259-1276.
- 479
- 480
- 481 43. Rodgers, T. and M. Rowland, *Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions*. Journal of Pharmaceutical Sciences, 2006. **95**(6): p. 1238-1257.
- 482
- 483
- 484 44. Sun, D., et al., *Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs*. Pharmaceutical Research, 2002. **19**(10): p. 1400-1416.
- 485
- 486
- 487 45. Gertz, M., et al., *Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data*. Drug Metab Dispos 2010. **38**(7): p. 1147-1158.
- 488
- 489
- 490 46. Marcellin, F., et al., *Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon*. Journal of Tropical Medicine and International Health, 2008. **13**(12): p. 1470-8.
- 491
- 492
- 493 47. Broekhuysen, J., et al., *Nitazoxanide: pharmacokinetics and metabolism in man*. International Journal of Clinical Pharmacology and Therapeutics, 2000. **38**(8): p. 387-394.
- 494
- 495 48. Belardo, G., et al., *Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro*. Antimicrobial Agents and Chemotherapy, 2015. **59**(2): p. 1061-1069.
- 496
- 497
- 498 49. Giuseppe Belardo, S.L.F., Orlando Cenciarelli, Stefania Carta, Jean-Francois Rossignol, M. Gabriella Santoro. *Nitazoxanide, a Novel Potential Anti-Influenza Drug, Acting in Synergism with Neuraminidase Inhibitors*. in *IDSA Annual Meeting*. 2011. Boston, MA, USA, Available from: <https://idsa.confex.com/idsa/2011/webprogram/Paper31075.html>.
- 499
- 500
- 501
- 502 50. Wang, M., et al., *Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro*. Cell Research, 2020. **30**(3): p. 269-271.
- 503
- 504 51. Chenel, M., et al., *Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes*. Journal of Pharmacokinetics and Pharmacodynamics, 2008. **35**(6): p. 635-659.
- 505
- 506
- 507
- 508 52. Nyberg, J., et al., *Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies*. British Journal of Clinical Pharmacology, 2015. **79**(1): p. 6-17.
- 509
- 510
- 511 53. Stockis, A., et al., *Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d*. International Journal of Clinical Pharmacology and Therapeutics, 2002. **40**(5): p. 221-227.
- 512
- 513
- 514 54. Haffizulla, J., et al., *Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial*. The Lancet Infectious Diseases, 2014. **14**(7): p. 609-618.
- 515
- 516
- 517 55. Tilmanis, D., et al., *The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide*. Antiviral Research, 2017. **147**: p. 142-148.
- 518
- 519 56. McCreary, E.K., J.M. Pogue, and o.b.o.t.S.o.I.D. Pharmacists, *Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options*. Open Forum Infectious Diseases, 2020. **7**(4).
- 520
- 521
- 522 57. Walls, A.C., et al., *Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein*. Cell, 2020. **181**(2): p. 281-292.e6.
- 523
- 524 58. Taubenberger, J.K. and D.M. Morens, *The pathology of influenza virus infections*. Annual review of pathology, 2008. **3**: p. 499-522.
- 525
- 526 59. Ranjbar, S., et al., *Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth*. iScience, 2019. **22**: p. 299-313.
- 527
- 528

529 **Study Highlights**

530 **What is the current knowledge on the topic?**

531 COVID-19, an acute respiratory infection caused by SARS-CoV-2, has been declared as a pandemic by
532 the World Health Organisation. Several repurposed drugs are being evaluated but currently there are
533 no robustly validated treatment or preventative medicines or regimens. Nitazoxanide has shown in
534 vitro activity against SARS-CoV-2, influenza and several other animal and human RNA viruses.

535 **What question did this study address?**

536 The manuscript describes the pharmacokinetics of tizoxanide, the active metabolite of nitazoxanide
537 using a physiologically-based pharmacokinetic (PBPK) model. The validated PBPK model was used to
538 estimate the optimal doses required for SARS-CoV-2 treatment or prevention such that >90% of the
539 simulated population would have tizoxanide concentrations in the plasma and lung above the
540 reported 90% effective concentration (EC₉₀) value of nitazoxanide for the entire dosing interval.

541 **What does this study add to our knowledge?**

542 There are no reported studies that identify treatment regimens of nitazoxanide for SARS-CoV-2
543 treatment or prevention. The current study provides evidence-based alternative dosing regimens of
544 nitazoxanide for SARS-CoV-2 treatment and prevention that exceeds antiviral EC₉₀s in key tissues and
545 organs for the duration of the dosing interval.

546 **How might this change clinical pharmacology or translational science?**

547 Efficacy of nitazoxanide has been demonstrated for uncomplicated influenza and the presented
548 predictions may help inform nitazoxanide dose selection for COVID19 clinical trials.

549


550 **Supplementary Table 1**

Drug	EC ₅₀ (μM)	EC ₅₀ (ng/ml)	EC ₉₀ (μM)	EC ₉₀ (ng/ml)	Influenza virus strain	Reference
Nitazoxanide	3.2	983	26	7989	A/Puerto Rico/8/1934 (H1N1)	[48]
	1.6	491	16.3	5008	A/WSN/1933 (H1N1)	
	3.2	983	20.8	6391	A/California/7/2009 (H1N1pdm09)	
	1.9	583	21.1	6483	Oseltamivir-resistant A/Parma/24/2009 (H1N1)	
	3.2	983	26.8	8235	A/Goose/Italy/296246/2003(H1N1)	
	1	307	13	3994	A/Parma/06/2007(H3N2)	
Average	2.4	722	20.7	6350	(for nitazoxanide)	
Tizoxanide	3.8	1000	33.9	9000	H1N1-PR8	[49]
	1.9	500	22.6	6000	H1N1-WSN	
	1.5	400	13.5	3600	H1N1-OST-R	
	5.7	1500	26.4	7000	H1N1-A/GO	
	3.8	1000	75.4	20000	H3N2-A/FI	
	1.1	300	26.3	7000	H3N2-AMD-R	
	3.4	900	22.6	6000	FLU-B	
Average	3.0	800	31.6	8371	(for tizoxanide)	


552 **Supplementary Figure 1**

553


A)



B)




C)




557

558

D)





559




560

561 **Supplementary Figure 1** Comparison of simulated and observed plasma concentration - time curve
562 of tizoxanide (TIZ) at fasted state. A) 500 mg, B) 1000 mg, C) 2000 mg, D) 3000 mg and E) 4000 mg


563 **Supplementary Figure 2**




565



566



567




568

569 **Supplementary Figure 2** Comparison of simulated and observed plasma concentration - time curve
570 of tizoxanide (TIZ) for single and multiple dosing regimen (where available) at fed state. A) 500 mg,
571 B) 1000 mg, C) 2000 mg, D) 3000 mg and E) 4000 mg


572 **Supplementary Figure 3**

573


574



575



576



577

578 **Figure 3** Predicted plasma and lung concentrations for optimal doses during fasted state at different
579 regimens reaching steady state – A) 2900 mg BID, B) 1600 mg TID and C) 1200 mg QID. TIZ –
580 tizoxanide, SD – standard deviation, solid red line indicates clinical C_{max} of 1 g single dose at fasted
581 state [29], solid green line represents clinical C_{max} of 500 mg single dose [35] at fasted state and the
582 dotted red line represents the EC_{90} of nitazoxanide for SARS-CoV-2 [50].